Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Apollomics Inc. (APLM) can feel like decoding a lab notebook: trial results, R&D spend, and partnership milestones sprawl across hundreds of SEC pages. If you have ever asked, “How do I navigate an Apollomics quarterly earnings report 10-Q filing?” or “Where are Apollomics insider trading Form 4 transactions recorded?”, this page is built for you.
Stock Titan’s AI-powered summaries turn dense disclosures into clear insights. Instead of wading through technical language, you’ll see key takeaways—cash runway, c-Met inhibitor trial status, E-selectin combo data, and material FDA updates—surface instantly. Real-time alerts push every Apollomics Form 4 insider transactions update, while our engine flags each 8-K material event for quick context.
All filing types are here and searchable: the annual report 10-K simplified for pipeline risk analysis, the proxy statement executive compensation details that link incentives to trial milestones, and S-3 capital raise documents that signal dilution risk. Want practical use cases? Compare R&D burn across quarters, monitor executive stock transactions before data readouts, or review an 8-K to understand how a partial clinical hold affects timelines. With comprehensive coverage and AI guidance, understanding Apollomics SEC documents with AI shifts from time-sink to strategic edge.
Popular searches already answered on this page include: “Apollomics SEC filings explained simply”, “Apollomics earnings report filing analysis”, and “Apollomics 8-K material events explained.” Whether you are an oncologist-turned-investor or a generalist portfolio manager, our platform keeps complex science and finance disclosures within reach.
Apollomics Inc. reported it has received US$3,900,000 from LaunXP related to their collaboration on vebreltinib in Asia (excluding mainland China, Hong Kong and Macau). The company stated the agreement remains in full force and effect, with both parties continuing to perform their obligations. Apollomics also noted this update is incorporated by reference into its registration statements on Form S-8 and Form F-3.
Apollomics Inc. changed its independent auditor and confirmed continued Nasdaq listing. On October 13, 2025, the Audit Committee dismissed Grant Thornton LLP and approved Marcum Asia CPAs LLP as auditor, effective immediately. Grant Thornton’s 2023 and 2024 reports had no adverse opinions, and the Company reports no disagreements through October 13, 2025. A material weakness disclosed as of December 31, 2023 was remediated during 2024.
On October 14, 2025, Nasdaq notified the Company it is in compliance; the appeal hearing was cancelled and the securities will remain listed.
Apollomics Inc. provided an operational continuity update, reversing prior plans to wind up after receiving $4.1 million in PIPE funding and appointing a new board and management team. The company will continue its global Phase 2 SPARTA trial of APL-101 (vebreltinib), a targeted therapy with positive results across more than 280 patients.
Management notified CROs and licensing partners of the transition and continuation of trials; contracts with current CROs are fully paid and up to date. Apollomics aims to support regulatory submissions in the U.S., EU and other markets, and plans to leverage Chinese approvals for MET-amplified NSCLC and GBM via its partner to pursue submissions in Southeast Asia, the Middle East and other regions. The company has 12 full-time employees and expects headcount to reach 15 by October 31, 2025, with a planned shift of roles from China to the U.S. and Taiwan.
Apollomics Inc. (APLM) disclosed two press-release exhibits: one announcing receipt of a Nasdaq delisting determination letter and a second stating the company has completed filing an appeal of the Nasdaq delisting order. The filings are attached as Exhibits 99.1 and 99.2. The current report is dated September 25, 2025 and is signed by Peter Lin, Chief Financial Officer. The document does not include financial results, specific reasons for the delisting determination, timelines for the appeal process, or details about potential remedies.
FAQ
What is the current stock price of APOLLOMICS (APLM)?
What is the market cap of APOLLOMICS (APLM)?
